CA3075440A1 - Pro-adm as a therapy monitoring marker for critcally ill patients - Google Patents
Pro-adm as a therapy monitoring marker for critcally ill patients Download PDFInfo
- Publication number
- CA3075440A1 CA3075440A1 CA3075440A CA3075440A CA3075440A1 CA 3075440 A1 CA3075440 A1 CA 3075440A1 CA 3075440 A CA3075440 A CA 3075440A CA 3075440 A CA3075440 A CA 3075440A CA 3075440 A1 CA3075440 A1 CA 3075440A1
- Authority
- CA
- Canada
- Prior art keywords
- sample
- proadm
- fragment
- level
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190912.0 | 2017-09-13 | ||
| EP17190912 | 2017-09-13 | ||
| PCT/EP2018/074722 WO2019053115A1 (en) | 2017-09-13 | 2018-09-13 | USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075440A1 true CA3075440A1 (en) | 2019-03-21 |
Family
ID=59887050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075440A Pending CA3075440A1 (en) | 2017-09-13 | 2018-09-13 | Pro-adm as a therapy monitoring marker for critcally ill patients |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200300864A1 (https=) |
| EP (2) | EP3682245A1 (https=) |
| JP (4) | JP7329503B2 (https=) |
| CN (2) | CN111065927B (https=) |
| BR (1) | BR112020004138A2 (https=) |
| CA (1) | CA3075440A1 (https=) |
| WO (2) | WO2019053116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026013199A1 (en) | 2024-07-12 | 2026-01-15 | Cezanne S.A.S. | Clinical immunoassay with early signal measurement |
| CN118976116B (zh) * | 2024-10-22 | 2025-01-24 | 四川大学华西医院 | 琥珀酰明胶在制备腹膜透析液中的用途以及一种含琥珀酰明胶、枸橼酸钠的腹膜透析液 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570703B1 (fr) | 1984-09-26 | 1988-07-08 | Commissariat Energie Atomique | Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents |
| US4882733A (en) | 1987-03-13 | 1989-11-21 | Ford Aerospace Corporation | Method and apparatus for combining encoding and modulation |
| FR2664699B1 (fr) | 1990-07-13 | 1995-08-18 | Cis Bio Int | Procede d'amplification du signal d'emission d'un compose luminescent. |
| DE69602756T2 (de) | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| KR100425525B1 (ko) | 2000-11-21 | 2004-03-30 | 재단법인서울대학교산학협력재단 | 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트 |
| US6864237B2 (en) * | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| CN101208602A (zh) * | 2005-04-15 | 2008-06-25 | 贝克顿迪金森公司 | 脓毒症的诊断 |
| DE102006034142A1 (de) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8298774B2 (en) | 2007-03-12 | 2012-10-30 | Biomedica Medizinprodukte Gmbh & Co Kg | Diagnosis of septic complications |
| PL2185937T5 (pl) | 2007-09-07 | 2014-12-31 | Univ Zuerich | Sposób wykrywania posocznicy u ludzi |
| ES2486268T3 (es) | 2007-11-16 | 2014-08-18 | Biocartis Nv | Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2131200A1 (en) * | 2008-06-04 | 2009-12-09 | BRAHMS Aktiengesellschaft | A marker for graft failure and mortality |
| US9229013B2 (en) | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
| JP5702371B2 (ja) * | 2009-05-27 | 2015-04-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害 |
| EP2438447B1 (en) | 2009-06-05 | 2015-02-18 | B.R.A.H.M.S GmbH | Detection of bacterial infections in subjects suffering from dyspnea. |
| US8383332B2 (en) | 2009-10-13 | 2013-02-26 | B.R.A.H.M.S. Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack |
| EP2545379B1 (en) | 2010-03-08 | 2015-09-30 | B.R.A.H.M.S GmbH | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
| WO2012059477A1 (en) | 2010-11-01 | 2012-05-10 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
| SG11201402362VA (en) * | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| CA2856150A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| US11067586B2 (en) * | 2011-11-16 | 2021-07-20 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
| DK2780717T3 (en) * | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| EP2976646B1 (en) * | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| US9597730B2 (en) * | 2013-04-19 | 2017-03-21 | United Technologies Corporation | Build plate and apparatus for additive manufacturing |
| US20180348235A1 (en) | 2015-11-27 | 2018-12-06 | B.R.A.H.M.S Gmbh | MR-proADM as marker for the extracellular volume status of a subject |
| EP4231018A3 (en) | 2016-07-08 | 2023-11-15 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| CA3033094A1 (en) | 2016-08-09 | 2018-02-15 | B.R.A.H.M.S Gmbh | Histones and/or proadm as markers indicating an adverse event |
-
2018
- 2018-09-13 WO PCT/EP2018/074723 patent/WO2019053116A1/en not_active Ceased
- 2018-09-13 BR BR112020004138-6A patent/BR112020004138A2/pt unknown
- 2018-09-13 WO PCT/EP2018/074722 patent/WO2019053115A1/en not_active Ceased
- 2018-09-13 JP JP2020515677A patent/JP7329503B2/ja active Active
- 2018-09-13 JP JP2020515760A patent/JP7366007B2/ja active Active
- 2018-09-13 EP EP18765656.6A patent/EP3682245A1/en active Pending
- 2018-09-13 US US16/646,637 patent/US20200300864A1/en active Pending
- 2018-09-13 CN CN201880059136.6A patent/CN111065927B/zh active Active
- 2018-09-13 US US16/646,639 patent/US12517138B2/en active Active
- 2018-09-13 EP EP18765657.4A patent/EP3682246A1/en active Pending
- 2018-09-13 CA CA3075440A patent/CA3075440A1/en active Pending
- 2018-09-13 CN CN201880059366.2A patent/CN111094986B/zh active Active
-
2023
- 2023-01-19 JP JP2023006500A patent/JP7544879B2/ja active Active
- 2023-10-10 JP JP2023175415A patent/JP2023181226A/ja not_active Abandoned
-
2025
- 2025-01-17 US US19/027,967 patent/US20250189539A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020004138A2 (pt) | 2020-09-08 |
| RU2020111719A3 (https=) | 2021-12-17 |
| JP2020533604A (ja) | 2020-11-19 |
| US20200300864A1 (en) | 2020-09-24 |
| US20250189539A1 (en) | 2025-06-12 |
| EP3682246A1 (en) | 2020-07-22 |
| CN111094986B (zh) | 2023-11-10 |
| WO2019053116A1 (en) | 2019-03-21 |
| JP7366007B2 (ja) | 2023-10-20 |
| CN111065927B (zh) | 2023-10-17 |
| US20200271667A1 (en) | 2020-08-27 |
| EP3682245A1 (en) | 2020-07-22 |
| CN111094986A (zh) | 2020-05-01 |
| WO2019053116A8 (en) | 2022-03-17 |
| JP2023181226A (ja) | 2023-12-21 |
| WO2019053115A1 (en) | 2019-03-21 |
| JP7329503B2 (ja) | 2023-08-18 |
| JP7544879B2 (ja) | 2024-09-03 |
| CN111065927A (zh) | 2020-04-24 |
| US12517138B2 (en) | 2026-01-06 |
| RU2020111719A (ru) | 2021-10-13 |
| JP2023041741A (ja) | 2023-03-24 |
| JP2020537117A (ja) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220187313A1 (en) | Diagnosis or Prognosis of Postsurgical Adverse Events | |
| US20250189539A1 (en) | Sample including pro-adm as a therapy monitoring marker for critcally ill patients | |
| US12000845B2 (en) | Method for discharging a patient from an intensive care unit | |
| JP2023095851A (ja) | 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ | |
| RU2782305C2 (ru) | Про-адм в качестве маркера мониторинга терапии для критически больных пациентов | |
| HK40077959A (en) | Pro-adm for therapy monitoring of intensive care unit patients | |
| RU2788885C2 (ru) | Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками | |
| HK40031519B (en) | Pct and pro-adm as markers for monitoring antibiotic treatment | |
| HK40069337A (en) | Proadrenomedullin as a marker for abnormal platelet levels | |
| HK40069336A (en) | Proadrenomedullin as a marker for abnormal platelet levels | |
| HK40032557B (en) | Proadrenomedullin as a marker for abnormal platelet levels | |
| HK40032557A (en) | Proadrenomedullin as a marker for abnormal platelet levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210920 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241018 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241203 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250327 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED Effective date: 20250724 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D136 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST AUTHORIZED Effective date: 20250724 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D135 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST RECEIVED Effective date: 20250724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250730 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250825 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250825 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250828 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250828 |